Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
- PMID: 27896496
- PMCID: PMC5366172
- DOI: 10.1007/s10096-016-2845-z
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
Abstract
Activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) in biofilm was investigated and the microbicidal biofilm concentrations (MBC) were determined. Biofilms obtained from ten MRSA and ten MRSE bloodstream isolates, collected from patients in the General Hospital of Vienna between 2012 and 2015, were incubated with dalbavancin in trypticase soy broth (TSB) in serial dilution from 0.0625 mg/l to 256 mg/l using a microtiter plate biofilm model. The plates were incubated for 24 h at 37 ° C and 50% humidity. Biofilms were fixed with 2.5% glutaraldehyde and stained with crystal violet. Subsequently the optical density (OD620) was used to measure the MBC, defined as the concentration of dalbavancin leading to a 50% reduction of biofilm. MBC for MRSA was 1 mg/l-4 mg/l (minimal inhibitory concentrations (MIC) 0.0312 mg/l-0.064 mg/l). MBC for MRSE was 2 mg/l-16 mg/l (MIC 0.023 mg/l-0.0625 mg/l). Dalbavancin successfully reduced MRSA and MRSE in biofilms, and therefore provides a promising option for the treatment of biofilm-associated infections.
Conflict of interest statement
Funding
This study has not been funded by any funding sources.
Potential conflicts of interest
F.T. reports an unrestricted research grant from Angelini Pharma®. K.D., T.S., C.SC., and B.DR. declare that they have no conflicts of interest.
Ethical approval
No vote of an ethics committee was needed, because this study does not include humans, human samples, animals or animal samples.
Informed consent
Informed consent could not be obtained, because this study is a laboratory study only, which does not involve human participants or human samples.
Figures
References
-
- Simor AE, Pelude L, Golding G. Determinants of outcome in hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infection: results from national surveillance in Canada, 2008–2012. Infect Control Hosp Epidemiol. 2016;37(4):390–397. doi: 10.1017/ice.2015.323. - DOI - PubMed
-
- Zajonz D, Wuthe L, Rodloff AC et al (2015) Infections of hip and knee endoprotheses: spectrum of pathogens and the role of multiresistant bacteria. Chirurg 87(4):332–339 [Article in German] - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
